Abstract
Indirect comparisons of new oral anticoagulants are performed with focus on their safety. Apixaban, an oral inhibitor of Xa factor, nowadays can be considered as a drug with very good safety profile according to randomized trials results and performed indirect comparisons.
Author supplied keywords
Cite
CITATION STYLE
APA
Sulimov, V. A., Napalkov, D. A., & Sokolova, A. A. (2013). Comparative efficacy and safety of new oral anticoagulants. Rational Pharmacotherapy in Cardiology, 9(4), 433–438. https://doi.org/10.20996/1819-6446-2013-9-4-433-438
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free